Deals and Financings   Hansoh Pharma of  Shanghai  announced a $456 million agreement to develop siRNA products from  South Korea 's OliX Pharma in Greater China; Abbisko, a  Shanghai  biopharma, completed a $226 million IPO in  Hong Kong  to support its small molecule therapies for cancer; Shanghai BioNova Pharma optioned  China  rights to a CD74 mAb for hematologic cancers from Sutro Biopharma in a $204 million agreement; Sciwind Biosciences, a  Hangzhou  biopharma focused on metabolic disease, closed a $70 million Series C funding for GLP-1 receptor agonist candidates; Chance Pharma of Hangzhou, an inhalation therapy company, completed a $30 million Series C financing led by Lapam Capital; GV20 Oncotherapy, a  Cambridge ,  MA - Shanghai  biotech, completed a Series B round to advance its lead immuno-oncology antibody candidate into the clinic; Eucure Bio, a subsidiary of  Beijing 's Biocytogen, will collaborate with Tracon Pharma to develop its CTLA-4 antibody for soft tissue sarcoma in  North America ;   Company News   Bristol-Myers wants to dissolve its $1.4 billion deal with  Beijing 's BeiGene because China has stopped distribution of Abraxane due to a manufacturing issue; AnchorDx of Guangzhou and South San Francisco 's Twist Bioscience launched their Pan-Cancer Methylation Panel in global markets; Shanghai Zai Lab will collaborate with Geneseeq, a Toronto-China company, to integrate new NGS services into clinical trials and advance precision care;  Trials and Approvals   Sirtex Medical, a division of China Grand Pharma and Healthcare, started a  China  trial of its selective internal radiation therapy in patients with liver cancer; Suzhou Kintor Pharma was approved to start a China Phase I combination trial of its ALK-1 antibody and a PD-1 to treat liver cancer.  Stock Symbols: (HK: 3692) (KOSDAQ: 226950) (HK: 2256) (NSDQ: STRO) (NSDQ: TCON) (NYSE: BMY) (NSDQ: BGNE; HK: 6160) (NSDQ: TWST) (NSDQ: ZLAB; HK: 9688) (HK: 9939) Share this with colleagues: // //